An Open-label, Phase II Study of ADX-2191 in Subjects With Retinitis Pigmentosa
Latest Information Update: 05 Jul 2023
At a glance
- Drugs Methotrexate (Primary)
- Indications Retinitis pigmentosa
- Focus Adverse reactions; Proof of concept
- Sponsors Aldeyra Therapeutics
- 29 Jun 2023 Status changed from active, no longer recruiting to completed.
- 29 Jun 2023 According to an Aldeyra Therapeutics media release, Ramiro S. Maldonado is the principal investigator for this trial.
- 29 Jun 2023 Positive topline results presented in an Aldeyra Therapeutics media release.